Key Takeaways:
- Epicutis is a science-backed, IP-driven skincare brand built around patented, biotechnology-derived actives.
- The business’s proprietary novel ingredients include TSC, Hyvia, and DSD.
- GroundForce Capital led the growth funding round.
BeautyMatter 2026 FUTURE50 brand Epicutis secured growth funding.
WHO: Founded in 2021 by Maxwell Stock, CEO and President, and Dr. Jeffry Stock, Board Chairman, Epicutis emerged from more than 20 years of bioscience research developed at Princeton University through its affiliate Signum Biosciences. Epicutis is a science-backed skincare brand built around its “Skin Health” positioning, offering clean, traceable, minimal formulations developed from proprietary, patent-protected actives. The brand has 4,100+ active professional accounts across medspas, dermatology practices, and spas nationwide.
WHY: The investment supports Epicutis's next phase of growth across the professional dermocosmetics channel, where they have built a fast-growing footprint among medspas, enabling the company to continue building brand awareness and developing cutting-edge skincare innovation.
IN THEIR OWN WORDS: “Epicutis exists because we believed skincare deserved real science —actives discovered in the lab, published in the literature, and trusted by practitioners before they ever reach a shelf,” said Maxwell Stock, co-founder, CEO, and President of Epicutis. “GroundForce understood that discipline from our very first conversation. This partnership lets us move faster on everything that matters: the discovery pipeline behind the brand, the professional channel we intend to lead, and the standard of proof we hold ourselves to.”
“...
